Hangzhou Baicheng Pharmaceutical Technology Co., Ltd
Special report on the deposit and use of raised funds in 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Basic information of raised funds
（1） Actual amount of raised funds and time of fund arrival
Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “the company” or “the company”) has publicly issued 27041667 RMB ordinary shares (A shares) to the public through the reply on Approving the registration of initial public offering shares of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (zjxk [2021] No. 3566) issued by China Securities Regulatory Commission, The issue price is 79.60 yuan per share, and the total raised capital is 215251669320 yuan. The raised capital after deducting 26187750398 yuan of underwriting and recommendation expenses is 189063918922 yuan, which has been remitted to the raised capital supervision account of the company by the lead underwriter Sinolink Securities Co.Ltd(600109) on December 15, 2021. In addition, after deducting 2720910081 yuan of additional external expenses directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, reporting accountant fee, lawyer fee and evaluation fee, the net amount of funds raised by the company this time is 18634 Dnake (Xiamen) Intelligent Technology Co.Ltd(300884) 1 yuan. The availability of the above raised funds has been verified by Tianjian Certified Public Accountants (special general partnership), who issued the capital verification report (Tianjian Yan [2021] No. 738).
（2） Use and balance of raised funds
Monetary unit: RMB
Item No. amount
Net amount of raised funds a 18634 Dnake (Xiamen) Intelligent Technology Co.Ltd(300884) 1
Project input B1
Accumulated amount as of the beginning of the period
Net interest income B2
Amount of current period project input C1
Item No. amount
Net interest income C267985114
Project input D1 = B1 + C1
Accumulated amount by the end of the period
Net interest income D2 = B2 + C267985114
The balance of funds raised should be e = a-d1 + D2186410993955
Actual balance of raised funds f 188831904036
Difference [note] g = E-F -2420910081
[note] the difference is 2420910081 yuan of external expenses directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, reporting accountant fee, lawyer fee, evaluation fee and so on.
2、 Deposit and management of raised funds
（1） Management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, The company complies with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange (revised in December 2020) (SZS [2020] No. 1292) and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM (SZS [2022] No. 14) In accordance with the provisions of relevant laws, regulations and normative documents, and in combination with the actual situation of the company, the measures for the administration of the raised funds of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the “measures”). In accordance with the management measures, the company has implemented a special account for the raised funds, established a special account for the raised funds in the bank, and together with the sponsor Sinolink Securities Co.Ltd(600109) signed the tripartite supervision agreement for the raised funds with Bank Of Hangzhou Co.Ltd(600926) science and technology sub branch, China Zheshang Bank Co.Ltd(601916) Binjiang sub branch, Hangzhou branch of Tailong commercial bank, China Merchants Bank Co.Ltd(600036) Qiantang sub branch, Agricultural Bank Of China Limited(601288) Binjiang sub branch, It defines the rights and obligations of all parties. There is no significant difference between the tripartite supervision agreement and the model tripartite supervision agreement of Shenzhen Stock Exchange, and the company has strictly complied with the raised funds.
（2） Storage of raised funds in special account
As of December 31, 2021, the company has five special accounts for raised funds, and the deposit of raised funds is as follows: amount unit: RMB yuan
Remarks on the balance of raised funds in the account number of the deposit bank
Bank Of Hangzhou Co.Ltd(600926) science and technology sub branch 3 Zhangjiagang Zhonghuan Hailu High-End Equipmentco.Ltd(301040) 1 Jinzhou Port Co.Ltd(600190) 2386365054770804 current deposit
China Zheshang Bank Co.Ltd(601916) Binjiang sub branch 331001013012010014852180045318083 current deposit
Tailong commercial bank Hangzhou Branch
33020010201 Fawer Automotive Parts Limited Company(000030) 95818064972651 current deposit
that ‘s ok
China Merchants Bank Co.Ltd(600036) Qiantang sub branch 57190891801012319666842498 current deposit
Current deposit of Binjiang sub branch
Total 188831904036 current deposit
3、 Actual use of raised funds this year
（1） Comparison table of use of raised funds
1. See Annex 1 of this report for the comparison table of the use of raised funds.
2. There is no use of over raised funds in this period.
（2） Description of abnormal conditions in the project invested by raised funds
There are no abnormalities in the investment projects of the company with raised funds.
（3） Description of the situation that the benefits of the investment projects with raised funds cannot be calculated separately
The company does not have the situation that the benefits of investment projects with raised funds cannot be calculated separately.
4、 Change the use of funds for investment projects with raised funds
The company does not change the investment projects of raised funds.
5、 Problems in the use and disclosure of raised funds
1. The information about the use of raised funds disclosed by the company is not disclosed in a timely, untrue, inaccurate or incomplete manner.
2. There are no violations in the deposit, use, management and disclosure of raised funds.
It is hereby announced.
Appendix 1 of the board of directors of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. on March 13, 2022
Comparison table of use of raised funds
Year 2021
Prepared by: Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. monetary unit: RMB 10000
Total amount of raised funds 18634301 total amount of raised funds invested in this year
forehead
Total amount of raised funds with changed purposes during the reporting period
The accumulated total amount of raised funds with changed purposes has been invested in the total amount of raised funds
forehead
Cumulative proportion of total raised funds with changed purposes
Whether the cumulative investment of the project has reached the target and whether the raised funds have reached the target by the end of the year (including part of the total amount of committed investment, investment amount (%) the expected effect achieved in the usable state)
Total investment direction change (1) (2) (3) = significant change in benefits and benefits on date (2) / (1)
1. Committed investment projects Hangzhou Baicheng Pharmaceutical Technology Co., Ltd
Limited company no 65051786505178 not applicable no
Committed investment items of headquarters and R & D Center Projects
Item – 6505178
Subtotal
Investment direction of over raised funds
1. Supplementary mobility -————
Subtotal of investment of over raised funds
Total -6505178
Circumstances and reasons for not reaching the planned progress or expected income (specific items are not applicable)
The description of major changes in the feasibility of the project is not applicable
The net amount of funds actually raised by the company’s initial public offering was 1863430100 yuan. After deducting the amount, purpose and use progress of the above-mentioned raised funds, the total amount of over raised funds was 1212912300 yuan. As of December 31, 2021, the unused over raised funds have been deposited in the special account for raised funds, and the specific purpose shall be determined according to the subsequent development needs of the company and relevant regulations.
The change of the implementation location of the project invested by raised funds is not applicable
The adjustment of the implementation mode of the project invested by raised funds is not applicable
The advance investment and replacement of the investment projects with raised funds are not applicable
Temporary use of idle funds is not applicable
The amount and reasons for the savings of raised funds in the implementation of the project are not applicable
The purpose and destination of unused raised funds are not applicable
Raised capital
